Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices | ||||||||||||||
By: PR Newswire Association LLC. - 20 Jun 2019 | Back to overview list |
|||||||||||||
FRANKLIN LAKES, N.J., June 20, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices in patients with peripheral arterial disease (PAD) in the superficial femoropopliteal artery (SFA): The panel discussed the benefits of paclitaxel-coated devices relative to the potential risks and noted strong evidence of benefit and recommended additional efforts to evaluate long-term safety. Additionally, BD presented its own data confirming that the benefits outweigh the risks for LUTONIX® Drug-Coated Balloons (DCBs) in SFA. Over the past several months, BD has been working diligently to obtain all available patient follow up data and collaborating with FDA, professional clinical organizations and industry to investigate the important issue of DCB safety. BD continues to stand behind the safety of its LUTONIX® DCBs and is committed to improving the quality of life for patients with PAD. BD will continue to collaborate with FDA, industry and professional organizations to collect and analyze data for the benefit of patients. To ensure patients with PAD continue to receive the best care possible, BD will continue to ensure physicians and patients have access to BD's broad range of treatment options for this serious disease. About BD
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-statement-on-fda-circulatory-system-devices-panel-regarding-paclitaxel-coated-devices-300872436.html SOURCE BD (Becton, Dickinson and Company) |
||||||||||||||
|
||||||||||||||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |